Development of respiratory syncytial virus (RSV) vaccines for infants
Development of respiratory syncytial virus (RSV) vaccines for infants
复制标题
为婴儿开发呼吸道合胞病毒 (RSV) 疫苗
DOI：
10.1016/s0163-4453(17)30205-0
复制
发表时间：
2017-06-01
影响因子：
28.2
通讯作者：
Sande, Charles J.
中科院分区：
文献类型：
--
作者：
Gerretsen, Hannah E.;Sande, Charles J.
2017年将是首次在儿童中分离出呼吸道合胞病毒60周年。尽管经过多年的共同努力，开发针对儿科呼吸道合胞病毒疾病的有效疫苗的目标仍然难以实现。阻碍研制有效疫苗的主要障碍之一是，严重疾病的年龄发病率在出生后的头3个月内达到高峰，因此提供干预的机会有限。除了这种复杂性之外，历史上失败的疫苗增加了在随后自然感染后患病和死亡的风险，这大大增加了评估现代疫苗的安全标准。本文回顾了婴幼儿呼吸道合胞病毒疫苗的发展历史，并分析了历史上疫苗失败的潜在原因。它还讨论了疫苗抗原设计的最新突破以及向血清阴性婴儿递送这些抗原的平台的逐步发展。(C) 2017年英国感染协会。Elsevier Ltd.出版。版权所有。
2017 will mark the 60th anniversary since the first isolation of RSV in children. In spite of concerted efforts over all these years, the goal of developing an effective vaccine against paediatric RSV disease has remained elusive. One of the main hurdles standing in the way of an effective vaccine is the fact that the age incidence of severe disease peaks within the first 3 months of life, providing limited opportunity for intervention. In addition to this complexity, the spectre of failed historical vaccines, which increased the risk of illness and death upon subsequent natural infection, has substantially increased the safety criteria against which modern vaccines will be assessed. This review traces the history of RSV vaccine development for young infants and analyses the potential reasons for the failure of historic vaccines. It also discusses recent breakthroughs in vaccine antigen design and the progressive evolution of platforms for the delivery of these antigens to seronegative infants. (C) 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.